Loading..

Sierra Oncology, Inc.(NasdaqGM:SRRA) dropped from Russell Microcap Value Index

2022-06-24 00:00:00

Sierra Oncology, Inc.(NasdaqGM:SRRA) dropped from Russell Microcap Value Index

Sierra Oncology, Inc.(NasdaqGM:SRRA) dropped from Russell 3000E Value Index

2022-06-24 00:00:00

Sierra Oncology, Inc.(NasdaqGM:SRRA) dropped from Russell 3000E Value Index

Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 3000 Growth Index

2022-06-24 00:00:00

Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 3000 Growth Index

Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 2000 Index

2022-06-24 00:00:00

Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 2000 Index

Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 2000 Growth Index

2022-06-24 00:00:00

Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 2000 Growth Index

Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell Small Cap Comp Growth Index

2022-06-24 00:00:00

Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell Small Cap Comp Growth Index

Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 3000 Index

2022-06-24 00:00:00

Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 3000 Index

Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell Small Cap Completeness Index

2022-06-24 00:00:00

Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell Small Cap Completeness Index

Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 2500 Index

2022-06-24 00:00:00

Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 2500 Index

Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 2000 Dynamic Index

2022-06-24 00:00:00

Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 2000 Dynamic Index

Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 3000E Index

2022-06-24 00:00:00

Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 3000E Index

Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 3000E Growth Index

2022-06-24 00:00:00

Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 3000E Growth Index

Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 2500 Growth Index

2022-06-24 00:00:00

Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 2500 Growth Index

Sierra Oncology, Inc. Announces Submission of New Drug Application for Momelotinib to US Food & Drug Administration

2022-06-17 11:00:00

Sierra Oncology, Inc. announced the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for momelotinib, an ACVR1 /ALK2, JAK1 and JAK2 inhibitor in development for the treatment of myelofibrosis. The NDA submission is based on the results from several Phase 2 and Phase 3 studies, including the recently completed MOMENTUM study. As with all new drug applications, the company expects the FDA to respond as to whether this submission is accepted within 60 days. Assuming the submission is accepted and a subsequent approval is granted, commercial launch of momelotinib is anticipated in 2023. MOMENTUM is a global, randomized, double-blind Phase 3 clinical trial of momelotinib versus danazol in patients with myelofibrosis who were symptomatic and anemic, and had been previously treated with an FDA-approved JAK inhibitor. The study was designed to evaluate the safety and efficacy of momelotinib for the treatment and reduction of the key hallmarks of disease: symptoms, blood transfusions (due to anemia) and splenomegaly (enlarged spleen). Results from the MOMENTUM study were presented at the 2022 Annual Meeting of the American Society of Clinical Oncology. The primary endpoint of the study is Total Symptom Score (TSS) reduction of >50% over the 28 days immediately prior to the end of Week 24 compared to baseline TSS, using the Myelofibrosis Symptom Assessment Form (MFSAF). Secondary endpoints included Transfusion Independence (TI) rate for >12 weeks immediately prior to the end of Week 24 with Hgb levels = 8 g/dL, and Splenic Response Rate (SRR) based on splenic volume reduction of >35% at Week 24. The study enrolled 195 patients based on a planned 180 patients across 21 countries. Danazol was selected as the treatment comparator given its use to ameliorate anemia in patients with myelofibrosis, as recommended by National Comprehensive Cancer Network (NCCN) and European Society of Medical Oncology (ESMO) guidelines. Patients were randomized 2:1 (MMB n = 130 and DAN n = 65) to receive either momelotinib or danazol. After 24 weeks of treatment, patients on danazol were allowed to crossover to receive momelotinib. Early cross-over to momelotinib was available for confirmed symptomatic splenic progression. Momelotinib is a potent, selective and orally bioavailable ACVR1 /ALK2, JAK1, JAK2 inhibitor under investigation for the treatment of myelofibrosis in symptomatic, anemic patients previously treated with an approved JAK inhibitor. More than 1,200 subjects have received momelotinib since clinical studies began in 2009, including approximately 1,000 patients treated for myelofibrosis, several of whom remain on treatment for over 12 years. Momelotinib is the first and only JAK inhibitor to demonstrate positive data for all key hallmarks of the disease—symptoms, splenic response and anemia.

Sierra Oncology, Inc. Announces Momelotinib Pivotal Phase 3 Data Receives Oral Presentation At American Society of Clinical Oncology Annual Meeting

2022-05-26 21:00:00

Sierra Oncology, Inc. announced two abstracts have been accepted into the program for the Annual Meeting of the American Society of Clinical Oncology (ASCO) being held June 3-7, 2022, in Chicago and online. An abstract presenting the full data from the pivotal phase 3 MOMENTUM study in myelofibrosis patients who are symptomatic and anemic has been selected for an oral presentation on June 7. An additional subset analysis from the trial evaluating safety and efficacy for patients with low platelet counts has been selected for poster presentation. Abstract: 7002: MOMENTUM: Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor: The primary and all key secondary results, as well as safety data, from the MOMENTUM pivotal Phase 3 trial of momelotinib will be presented in an oral presentation by Ruben Mesa, MD, co-Principal Investigator of the study. Key data to be presented include: Primary Endpoint of Total Symptom Score (TSS) of >50%: 25% in the MMB arm vs. 9% in the control arm (p=0.0095); Secondary Endpoint of Transfusion Independence (TI): 31% in the MMB arm vs. 20% in the control arm (one-sided p=0.0064; non-inferiority); Secondary Endpoint of Splenic Response Rate (SRR) >35%: 23% in the MMB arm vs. 3% in the control arm (p=0.0006); SRR of >25% was 40% in the MMB arm and 6% in the control arm. A trend toward improved overall survival is demonstrated in the MMB arm based on data up to Week 24 (p=0.0719) and overall (p=0.3510); The rate of Grade 3 or worse adverse events in the randomized treatment period was 54% in the MMB arm and 65% in the control arm. Serious treatment emergent adverse events were 35% in the MMB arm and 40% in the control arm. The most frequent non-hematologic adverse events were diarrhea, nausea, asthenia, pruritis and increased blood creatinine; Mean baseline characteristics for all patients were TSS of 27, Hemoglobin (Hgb) of 8 g/dL and platelet count of 145 x 109/L. Abstract 7061: Thrombocytopenic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) [MOMENTUM]: Abstract 7061 will highlight an analysis of MOMENTUM patients with baseline platelet counts as low as 25 x 109/L on study endpoints, including Week 24 TSS reduction of >50% from baseline, transfusion independence rates, and SRR of >35% from baseline. Results to be presented include: Of the 195 patients enrolled in the MOMENTUM study, 124, 100 and 31 patients had baseline platelet counts of less than 150, 100, and 50 x 109/L, respectively.; In patients with baseline platelets <100 x 109/L (MMB: n=66; DAN: n=34): TSS responder proportion was 29% in the MMB arm and 15% in the control arm; TI response proportion was 27% in the MMB arm and 21% in the control arm; SRR was 20% in the MMB arm and 6% in the control arm; In patients with baseline platelets <50 x 109/L (MMB: n=18; DAN: n=13): TSS responder proportion was 22% in the MMB arm and 8% in the control arm; TI response proportion was 17% in the MMB arm and 15% in the control arm; SRR was 22% in the MMB arm and 0% in the control arm; The broader thrombocytopenic subgroup with baseline platelets <150 x 109/L demonstrated similar efficacy and safety as described in the published abstract; In patients with baseline platelets below 50 x 109/L, mean platelet levels remained stable over time in both the MMB and control arms; Overall Survival directionally favored the MMB arm, consistent with the survival results in the intent-to-treat population; The proportion of patients who experience Grade 3 or higher treatment-emergent adverse events were comparable between the study arms; Mean baseline characteristics for patients with baseline platelets <100 x 109/L included TSS of 28 and 25 and Hgb of 8.1 and 7.8 g/dL for the MMB and control arms, respectively. In thrombocytopenic, symptomatic and anemic patients with myelofibrosis, including those with platelets as low as 25 x 109/L, momelotinib was administered safely and demonstrated improvements in symptom responses, transfusion independence rates and spleen responses as compared to danazol. Consistent with the overall intent-to-treat MOMENTUM population, platelets levels remained stable over time, survival favored momelotinib versus danazol, and the safety profile was generally maintained in thrombocytopenic myelofibrosis patients receiving momelotinib.

Sierra Oncology, Inc., Special/Extraordinary Shareholders Meeting, Jun 29, 2022

2022-05-16 20:09:00

Sierra Oncology, Inc., Special/Extraordinary Shareholders Meeting, Jun 29, 2022, at 10:00 Pacific Standard Time. Agenda: To consider and vote on the proposal to adopt the Agreement and Plan of Merger, dated April 12, 2022, between GlaxoSmithKline plc, Orikum Acquisition Inc. and Sierra Oncology, as it may be amended from time to time; to consider and vote on the proposal to approve, on a non-binding, advisory basis, the compensation that will or may become payable by Sierra Oncology to its named executive officers in connection with the merger of Orikum Acquisition Inc., an indirect wholly owned subsidiary of GlaxoSmithKline plc, with and into Sierra Oncology; to consider and vote on any proposal to adjourn the special meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to adopt the merger agreement at the time of the special meeting; and to consider other matters if any.

Sierra Oncology, Inc. - Shareholder/Analyst Call

2022-05-16 20:09:00

Sierra Oncology, Inc. - Shareholder/Analyst Call

GlaxoSmithKline plc (LSE:GSK) entered into an agreement to acquire Sierra Oncology, Inc. (NasdaqGM:SRRA) for $1.3 billion.

2022-04-13 00:00:00

GlaxoSmithKline plc (LSE:GSK) entered into an agreement to acquire Sierra Oncology, Inc. (NasdaqGM:SRRA) from Frazier Healthcare VI, L.P., Frazier Life Sciences VIII, L.P., Frazier Life Sciences Public Fund, L.P., all managed by Frazier Management, L.L.C., and others for $1.3 billion on April 12, 2022. Under the terms of the agreement, the acquisition will be effected through a one-step merger in which the shares of Sierra Oncology outstanding will be cancelled and converted into the right to receive $55 per share in cash. Under the terms of the agreement, the acquisition will be effected through a one-step merger in which the shares of Sierra Oncology outstanding will be cancelled and converted into the right to receive $55 per share in cash. Furthermore, each of the Sierra Oncology’s stock options will receive an amount in cash equal to the excess of offer per share over the exercise price and Series A warrants will receive $45.98 per warrant. All pre-funded warrants will be deemed exercised in full as a “cashless exercise” and would receive $55 per warrant. Sierra Oncology shall pay a termination fee of $70 million to GlaxoSmithKline. The transaction is subject to customary conditions, including the approval of the merger by at least a majority of the issued and outstanding shares of Sierra Oncology and the expiration or earlier termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The transaction was unanimously approved by the Board of Directors of Sierra Oncology. The initial waiting period under the HSR Act is set to expire on May 31, 2022. On May 31, 2022, the waiting period under the HSR Act expired with respect to the Merger. The shareholders meeting of Sierra Oncology is scheduled on June 29, 2022. The transaction is expected to close in the third quarter of 2022 or before. GSK will account for the transaction as a business combination and expects it to be accretive to adjusted EPS in 2024, the expected first full year of momelotinib’s sales. PJT Partners is acting as financial advisor and Benet O’Reilly and Kimberly Spoerri of Cleary Gottlieb Steen & Hamilton LLP is serving as legal counsel to GSK in connection with the transaction. Lazard Freres & Co. LLC is acting as financial advisor and fairness opinion provider while Robert Ishii, Remi Korenblit and Michael Nordtvedt of Wilson Sonsini Goodrich & Rosati, is serving as legal counsel to Sierra Oncology. Graham Robinson and Marie L Gibson of Skadden represented Lazard Freres & Co. LLC in the transaction. Innisfree M&A Inc. acted as proxy solicitor and American Stock Transfer & Trust Company, LLC acted as transfer agent to Sierra Oncology. Sierra Oncology has agreed to pay a fee of $25,000 to Innisfree for its services. Sierra Oncology will pay Lazard, a transaction fee of approximately $44 million, payable upon the consummation of the merger, of which $2 million became payable upon delivery of the fairness opinion.

Sierra Oncology, Inc. Presents at 4th Annual Guggenheim Oncology Day, Feb-10-2022 12:00 PM

2022-02-03 12:00:00

Sierra Oncology, Inc. Presents at 4th Annual Guggenheim Oncology Day, Feb-10-2022 12:00 PM. Speakers: Stephen George Dilly, President, CEO & Director.

Sierra Oncology, Inc. Presents at B. Riley Securities Oncology Investor Conference 2022, Jan-28-2022 02:30 PM

2022-01-27 12:00:00

Sierra Oncology, Inc. Presents at B. Riley Securities Oncology Investor Conference 2022, Jan-28-2022 02:30 PM. Speakers: Stephen George Dilly, President, CEO & Director.

Sierra Oncology, Inc. has completed a Follow-on Equity Offering in the amount of $134.999074 million.

2022-01-27 00:00:00

Sierra Oncology, Inc. has completed a Follow-on Equity Offering in the amount of $134.999074 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 4,074,075 Price\Range: $27 Discount Per Security: $1.62 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 925,925 Price\Range: $26.999 Discount Per Security: $1.6199

Certain Common Stock of Sierra Oncology, Inc. are subject to a Lock-Up Agreement Ending on 28-APR-2022.

2022-01-27 00:00:00

Certain Common Stock of Sierra Oncology, Inc. are subject to a Lock-Up Agreement Ending on 28-APR-2022. These Common Stock will be under lockup for 91 days starting from 27-JAN-2022 to 28-APR-2022. Details: The executive officers, directors and certain of stockholders of equity securities have entered into a lock up agreement pursuant to which, they will not to sell, offer to sell, contract to sell or lend any shares of common stock or any related securities, effect any short sale, or establish or increase any “put equivalent position”, or liquidate or decrease any “call equivalent position”, pledge, hypothecate, grant any security interest in, otherwise transfer or dispose of any shares of common stock or any related securities currently or hereafter owned either of record or beneficially (as defined in Rule 13d-3 under the Exchange Act) by the lock-up party or the spouse of the lock-up party, an immediate family member (as defined in Rule 16a-1(e) under the Exchange Act) of the lock-up party, or an immediate family member of the lock-up party’s spouse (each a, “family member”); enter into any swap, hedge or similar arrangement or agreement that transfers or is designed to, intended to, or which could reasonably be expected to lead to or result in the transfer of, in whole or in part, the economic risk of ownership of shares of common stock or any related securities; make any demand for, or exercise any right with respect to, the registration under the Securities Act of the offer and sale of any shares of common stock or of any related securities, or cause to be filed a registration statement, prospectus or prospectus supplement (or an amendment or supplement thereto) with respect to any such registration; or publicly announce an intention to do any of the foregoing any common stock or securities convertible into or exchangeable or exercisable for common stock, for a period of 90 days after the date of the final prospectus, without the prior written consent of Jefferies LLC, on behalf of the underwriters.

Certain Options of Sierra Oncology, Inc. are subject to a Lock-Up Agreement Ending on 28-APR-2022.

2022-01-27 00:00:00

Certain Options of Sierra Oncology, Inc. are subject to a Lock-Up Agreement Ending on 28-APR-2022. These Options will be under lockup for 91 days starting from 27-JAN-2022 to 28-APR-2022. Details: The executive officers, directors and certain of stockholders of equity securities have entered into a lock up agreement pursuant to which, they will not to sell, offer to sell, contract to sell or lend any shares of common stock or any related securities, effect any short sale, or establish or increase any “put equivalent position”, or liquidate or decrease any “call equivalent position”, pledge, hypothecate, grant any security interest in, otherwise transfer or dispose of any shares of common stock or any related securities currently or hereafter owned either of record or beneficially (as defined in Rule 13d-3 under the Exchange Act) by the lock-up party or the spouse of the lock-up party, an immediate family member (as defined in Rule 16a-1(e) under the Exchange Act) of the lock-up party, or an immediate family member of the lock-up party’s spouse (each a, “family member”); enter into any swap, hedge or similar arrangement or agreement that transfers or is designed to, intended to, or which could reasonably be expected to lead to or result in the transfer of, in whole or in part, the economic risk of ownership of shares of common stock or any related securities; make any demand for, or exercise any right with respect to, the registration under the Securities Act of the offer and sale of any shares of common stock or of any related securities, or cause to be filed a registration statement, prospectus or prospectus supplement (or an amendment or supplement thereto) with respect to any such registration; or publicly announce an intention to do any of the foregoing any common stock or securities convertible into or exchangeable or exercisable for common stock, for a period of 90 days after the date of the final prospectus, without the prior written consent of Jefferies LLC, on behalf of the underwriters.

Certain Warrants of Sierra Oncology, Inc. are subject to a Lock-Up Agreement Ending on 28-APR-2022.

2022-01-27 00:00:00

Certain Warrants of Sierra Oncology, Inc. are subject to a Lock-Up Agreement Ending on 28-APR-2022. These Warrants will be under lockup for 91 days starting from 27-JAN-2022 to 28-APR-2022. Details: The executive officers, directors and certain of stockholders of equity securities have entered into a lock up agreement pursuant to which, they will not to sell, offer to sell, contract to sell or lend any shares of common stock or any related securities, effect any short sale, or establish or increase any “put equivalent position”, or liquidate or decrease any “call equivalent position”, pledge, hypothecate, grant any security interest in, otherwise transfer or dispose of any shares of common stock or any related securities currently or hereafter owned either of record or beneficially (as defined in Rule 13d-3 under the Exchange Act) by the lock-up party or the spouse of the lock-up party, an immediate family member (as defined in Rule 16a-1(e) under the Exchange Act) of the lock-up party, or an immediate family member of the lock-up party’s spouse (each a, “family member”); enter into any swap, hedge or similar arrangement or agreement that transfers or is designed to, intended to, or which could reasonably be expected to lead to or result in the transfer of, in whole or in part, the economic risk of ownership of shares of common stock or any related securities; make any demand for, or exercise any right with respect to, the registration under the Securities Act of the offer and sale of any shares of common stock or of any related securities, or cause to be filed a registration statement, prospectus or prospectus supplement (or an amendment or supplement thereto) with respect to any such registration; or publicly announce an intention to do any of the foregoing any common stock or securities convertible into or exchangeable or exercisable for common stock, for a period of 90 days after the date of the final prospectus, without the prior written consent of Jefferies LLC, on behalf of the underwriters.

Guggenheim Securities, LLC, 4th Annual Guggenheim Oncology Day, Feb 09, 2022 through Feb 11, 2022

2022-01-24 11:50:00

Guggenheim Securities, LLC, 4th Annual Guggenheim Oncology Day, Feb 09, 2022 through Feb 11, 2022.

B. Riley Securities, Inc., B. Riley Securities Oncology Investor Conference 2022, Jan 27, 2022 through Jan 28, 2022

2021-12-30 06:47:00

B. Riley Securities, Inc., B. Riley Securities Oncology Investor Conference 2022, Jan 27, 2022 through Jan 28, 2022.

Sierra Oncology Reports Baseline Ferritin Differentially Predicts Week 24 Transfusion Independence Response in Myelofibrosis Patients

2021-12-13 23:34:00

Sierra Oncology, Inc. announced data from new retrospective analyses of the Phase 3 SIMPLIFY studies demonstrate baseline ferritin differentially predicts Week 24 Transfusion Independence Response for momelotinib and ruxolitinib in patients with myelofibrosis. The data were presented at the 63rdAmerican Society of Hematology (ASH) Annual Meeting being held virtually and in Atlanta, GADecember 11-14, 2021. Baseline Serum Ferritin Differentially Predicts W24 Transfusion Independence Response for Momelotinib and Ruxolitinib in Patients with Myelofibrosis. Myelofibrosis is characterized by the presentation of constitutional symptoms, splenomegaly and anemia, with the degree of anemia and transfusion dependence being among the most important predictors of overall survival. Dr. Stephen Oh, MD, PhD, Washington University School of Medicine in St. Louis and Siteman Cancer Center, noted how the analyses identified pre-treatment serum ferritin level as the most predictive biomarker for the treatment effect of momelotinib versus ruxolitinib on Week 24 Transfusion Independence Response (TI-R) in the SIMPLIFY-1 (JAK inhibitor-naïve) and SIMPLIFY-2 (JAK-inhibitor experienced) studies. Key results for SIMPLIFY-1 include: Ruxolitinib was associated with a significantly greater increase in ferritin levels over time compared with momelotinib, irrespective of baseline ferritin, highlighting the differential treatment impact on serum ferritin between the two agents. Baseline hemoglobin (Hgb), an indicator of anemic status, differentially predicted Week 24 TI-R in patients randomized to momelotinib or ruxolitinib. Baseline ferritin also differentially predicted Week 24 TI-R in patients randomized to momelotinib or ruxolitinib. For patients with baseline ferritin between 90-650 ng/mL, momelotinib-treated patients had a higher Week 24 TI-R rate than ruxolitinib-treated patients [72% vs. 38%, OR 4.21 (95% CI: 2.24, 7.89); p=0.0439]. In patients with baseline Hgb <12 g/dL, baseline ferritin levels provided additional, differential predictive value for Week 24 TI-R. The differential treatment effect between momelotinib and ruxolitinib was highest for anemic patients with baseline ferritin between 90-650 ng/ml. No correlation was observed between baseline ferritin and Week 24 splenic or symptom response rates. Findings from SIMPLIFY-1 were independently confirmed in the JAK inhibitor experienced setting of the SIMPLIFY-2 study, where Hgb and ferritin each differentially predicted Week 24 TI-R in patients randomized to momelotinib or best available therapy (BAT; 88.5% ruxolitinib), and baseline ferritin predicted additional, differential predictive value for Week 24 TI-R in patients with Hgb <12 g/dL. For patients with baseline ferritin between 90-650 ng/mL, momelotinib-treated patients had higher Week 24 TI-R than those treated with BAT [53% vs 22%, OR 2.27 (95% CI: 1.01,12.77); p=0.03099]. These data suggest that ferritin may be useful in treatment decision making in myelofibrosis, especially in patients with anemia and ferritin 90-650 ng/mL, in which momelotinib demonstrates a greater TI effect than ruxolitinib. Future evaluation may be made in forthcoming clinical trials to further examine the correlation between ferritin and TI response.

Sierra Oncology, Inc. - Special Call

2021-12-06 00:00:00

To review momelotinib data from the Phase 3 SIMPLIFY studies

Sierra Oncology, Inc. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-18-2021 03:00 AM

2021-11-12 12:00:00

Sierra Oncology, Inc. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-18-2021 03:00 AM. Venue: London, United Kingdom. Speakers: Stephen George Dilly, President, CEO & Director.

Sierra Oncology, Inc. has filed a Follow-on Equity Offering in the amount of $137.1 million.

2021-11-05 00:00:00

Sierra Oncology, Inc. has filed a Follow-on Equity Offering in the amount of $137.1 million. Security Name: Common Stock Security Type: Common Stock Security Name: Common Stock Security Type: Common Stock Securities Offered: 5,049,720 Price\Range: $17.248481 Transaction Features: At the Market Offering

Sierra Oncology, Inc. has filed a Shelf Registration in the amount of $200 million.

2021-11-05 00:00:00

Sierra Oncology, Inc. has filed a Shelf Registration in the amount of $200 million. Security Name: Common Stock Security Name: Preferred Stock Security Name: Debt Securities Security Name: Depositary Shares Security Name: Warrants Security Name: Subscription Rights Security Name: Units Transaction Features: Omnibus/Universal Shelf Registration

Sierra Oncology, Inc. Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM

2021-09-07 11:00:00

Sierra Oncology, Inc. Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM. Venue: Lotte New York Palace Hotel, New York City, New York, United States. Speakers: Stephen George Dilly, President, CEO & Director.

Sierra Oncology, Inc. Presents at Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit, Sep-21-2021 02:05 PM

2021-09-07 11:00:00

Sierra Oncology, Inc. Presents at Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit, Sep-21-2021 02:05 PM.

Sierra Oncology, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-28-2021 04:00 PM

2021-09-07 11:00:00

Sierra Oncology, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-28-2021 04:00 PM. Venue: New York, United States. Speakers: Stephen George Dilly, President, CEO & Director.

Sierra Oncology Provides Update to Momelotinib Development Timeline

2021-08-09 11:00:00

Sierra Oncology, Inc. updated guidance on the development timeline for its lead product candidate, momelotinib. The company now expects topline data from the Phase 3 registration-enabling MOMENTUM study by February 2022, and assuming positive results, the company plans to file a New Drug Application with the U.S. Food & Drug Administration in second quarter of 2022.

Sierra Oncology, Inc. - Special Call

2021-08-05 20:05:00

To discuss Exclusive Global In-Licensing Agreement with AstraZeneca

Oppenheimer & Co. Inc., Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit, Sep 20, 2021 through Sep 23, 2021

2021-07-21 14:31:00

Oppenheimer & Co. Inc., Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit, Sep 20, 2021 through Sep 23, 2021.

Sierra Oncology, Inc. Presents at 2nd Annual JAK Inhibitors Drug Development Digital Event, Jun-29-2021 through Jul-01-2021

2021-06-29 12:23:00

Sierra Oncology, Inc. Presents at 2nd Annual JAK Inhibitors Drug Development Digital Event, Jun-29-2021 through Jul-01-2021. Presentation Date & Speakers: Jul-01-2021, Barbara Klencke, Chief Development Officer.

Hanson Wade Limited, 2nd Annual JAK Inhibitors Drug Development Digital Event, Jun 29, 2021 through Jul 01, 2021

2021-06-29 12:00:00

Hanson Wade Limited, 2nd Annual JAK Inhibitors Drug Development Digital Event, Jun 29, 2021 through Jul 01, 2021.